| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that benralizumab be reimbursed as an add-on maintenance treatment for adult patients with severe eosinophilic asthma, if the following criteria and conditions are met: Patient is inadequately controlled with high-dose inhaled corticosteroids (ICSs) and one or more additional asthma controller(s) (e.g., long-acting beta agonists [LABAs]), if one of the following two clinical criteria is met: Blood eosinophil count of ≥ 300 cells/μL AND has experienced two or more clinically significant asthma exacerbations in the past 12 months OR Blood eosinophil count of ≥ 150 cells/μL AND is treated chronically with oral corticosteroids (OCSs). Benralizumab should not be prescribed to patients who smoke. Benralizumab should not be used in combination with other biologics used to treat asthma
|
|---|